What if the decisions neurosurgeons make during surgery — such as about how much tissue to remove — could be guided by immediate
results from spectroscopic methods? A number of spectroscopy researchers are seeking to advance methods to make that both
possible and practical. One such researcher is Allison Stelling, who recently completed her PhD under Professor Peter Tonge
at Stony Brook University in New York. Stelling is currently at the Center for Materials Genomics at Duke University, in Durham,
North Carolina, working under Professor Stefano Curtarolo. Previously, during a post as a scientific research associate in
the Clinical Sensing and Monitoring department in the Faculty of Medicine at Dresden University of Technology, in Dresden,
Germany, Stelling and colleagues studied the use of infrared (IR) spectroscopy for use in intraoperative diagnostics during
brain surgery. Spectroscopy recently spoke to Stelling about that work, which was published in the journal PLoS ONE (1).
When using IR spectroscopy to examine freshly resected brain tissue in an operating room, what are you trying to achieve?
The end goal is to be able to detect the hard-to-see tumor borders during operations, because incomplete removal is linked
to recurrence in many brain tumors. In soft tissues like the brain, these borders shift during the operation from preoperative
magnetic resonance imaging (MRI) images. IR can give contrast in these low-contrast situations, and thus aid in reducing the
number of surgeries a patient must endure. This initial study was focused more on determining where reliable spectral differences
are between normal and tumor in fully hydrated tissue. Further studies will be needed to see how the identified signals "titrate"
between normal and tumor tissue.
TOM FULLUM/GETTY IMAGES
When analyzing brain tumors with IR spectroscopy, what biomarkers are you measuring? How precisely can these markers be differentiated
in healthy and cancerous tissue, and to what extent do individual variances occur? Have the biomarkers been validated?
Chemicals produced by the tumor itself and then sensed by IR serve as the biomarkers. In the attenuated total reflectance
Fourier transform infrared (ATR-FTIR) spectra from tumor tissues, this results in fairly dramatic shifts in frequency and
changes in absorbance. While full interpretation on a chemical level must await purification and structural characterization
studies, it is apparent that there do seem to be reasonably large changes in the ATR-FTIR between the control brain tissues
and the tumor ones.
In our recent study, we found a particular region that contains signals from extracellular molecules like collagen, whose
triple helix structures give it a very distinctive IR signal. Collagens are overexpressed in many tumors, resulting in large
changes in the IR. These changes were plotted in the recent paper we published in PLoS ONE (1). Dr. Deirdre Toher, a statistician at the University of the West of England in Bristol, helped me with some of the basic
spectral preprocessing in large batches for the study.
A major lesson I gained from this trial — and when doing my literature survey for the recent publication — addresses your
question about how to identify so-called "spectral biomarkers" or "fingerprints" for disease. Doing controls with healthy
tissues and comparing and contrasting them with diseases can allow us to first determine where reliable differences occur.
Comparison with tissues known to overexpress certain chemicals can help assign bands and determine roughly their percent contribution
to the overall tissue spectrum.
Inter-individual variance for this measurement was something I was quite concerned about, which is why Dr. Ordtrud Uckermann,
a neuroscientist at the Department of Neurosurgery in the Dresden University Hospital, and I designed a small control study
to obtain the IR signals from normal, healthy mouse brains. The variation among the five individual animals was much lower
than I expected it to be (particularly for waterlogged materials), and forthcoming manuscripts on this trial will illuminate
What will be most interesting to see is how the IR spectra change between patients with the same diagnosis using traditional
histochemistry. IR shall likely be much more sensitive to intrinsic, biochemical-level inter-individual differences in the
phenotype of the tumor than any morphology-based method. This information will help biomedical scientists in the future design
personalized treatments with physicians based on a patient's unique biochemistry.
This is the preclinical trial, so validation is the next step. These initial results are reasonably promising, however, and
illustrate that the core idea is sound.